TYSONS CORNER, Va. and PETAH TIKVA, Israel, June 10, 2026 /PRNewswire/ -- Cellebrite DI Ltd. $CLBT (+1,47 %) (Nasdaq: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced Cellebrite Genesis general availability. Genesis allows investigators faced with increasing crime and data types to quickly and intuitively interrogate digital evidence using the product's agentic AI capabilities to surface intelligence in minutes rather than days or weeks.
@Get_Rich_or_Die_Tryin fühl dich angepingt (geht irgendwie nicht) warum gibst du deinem Kult keine News 👋🤣
What's New at General Availability
The general availability release expands Genesis with capabilities shaped directly by Early Access customer feedback:
- Warrant-Bound Search. Investigators can set Genesis to search only within the parameters of their search warrant, so the AI stays inside what the law allows on every case.
- Location Intelligence. A new map view shows where people and events moved across a case, making patterns easier to spot.
- Upgraded Media Analysis. Smarter analysis of images, video and audio, including transcription and translation of approximately 120 languages, showing who said what, line by line.
- Refined Agentic Accuracy. The AI is better at knowing what it can and cannot do and relaying that to the user which ultimately means cleaner discoveries, answers and tighter connections back to the source evidence.
"Genesis was built on the belief that evidence should move at the speed of the case. When the people closest to an investigation can act sooner, justice moves faster, and communities, nations and businesses are better protected," said Shiven Ramji, president, products and technology, Cellebrite. "General availability means agencies of any size can now operationalize agentic AI on real casework with capability that fortifies the chain of custody, delivers source traceability and is grounded in the operational discipline that public safety demands."
Source: investors.cellebrite.com
